Cogentum client Acrux today announced one of the biggest licensing  deals in Australian Biotech history. The deal with Eli Lilly ranks up there as one of the biggest outcomes for an Australian biotech. From the announcements you will see that this is a superb result for any Australian company seeking to license it’s technology.

Cogentum worked [...]

[Read more →]

Have you ever wondered how easy it would be if you could pay with your credit card anywhere, at any time?
Hmmm, nice idea, but the problem has always been a lack of terminals. After all, not many garage sales have their own EFTPOS terminal, right?
WRONG! Silicon Valley based start up firm Square have busted this [...]

[Read more →]

When I am really sick, I see a Doctor. Why? Because they are trained to assess the symptoms/data/evidence I present with. In essence I trust that they know what they are doing.
This trust is based on my understanding that through a unique and powerful combination of training, education and experience they are able to assess the data and from [...]

[Read more →]

One of the leading academics and authors on Business and Management Dr Henry Minztberg has written a thought provoking piece in the MIT Sloan Management Review on whether the executive bonus schemes should stay or be scrapped.
Mintzberg says, “Executive bonuses—especially in the form of stock and option grants—represent the most prominent form of legal corruption that has been [...]

[Read more →]

For the last 8 months we have been working with Neopec, a new company that is commercialising a revolutionary approach to breast reconstruction using technology developed at Melbourne, Australia’s Bernard O’Brien Institute of Microsurgery and the Australian Tissue Engineering Center.
Neopec will allow women who have been through the trauma of breast cancer and mastectomy to re-grow [...]

[Read more →]

Great news is continuing to emerge from the Australian biotech sctor.
We are glad to see that one of our clients, Acrux, is leading the charge as it continues to build a cogent story for its investors and the market.
Equally pleasing is the rapid progress of Universal Biosensors (sadly, not a client!). This company is, in our [...]

[Read more →]

Web3.0 has arrived

[Read more →]

The following piece appeared in September 28th edition of Bioshares #330, Australia’s leading analysis and commentary on the Biotech sector. It summarises our out take on the 2009 Bioshares conference held at Thredbo in September.

Don’t worry about your Technology, show me the Strategy

The 2009 Thredbo summit graphically illustrated why strategy is becoming increasingly more valuable [...]

[Read more →]

Malcolm Gladwell is one of our favourite authors. His book the Tipping Point became a phenomenon. We recently noted his latest article (Cocksure) in the New Yorker. It is a wonderful description of the dangers of over confidence and how this contributed to the spectacular fall of Bear Stearns. A great read.

[Read more →]

Did you ever buy a Polaroid instant camera?
Probably.
If you did, and many did, you probably marvelled at the film and the organic process involved in taking pictures.
You weren’t the only one. Polaroid film also gained a massive following amongst professional and amateur photographers who valued its unique characteristics. Specifically they loved the freedom the film [...]

[Read more →]